Gene therapy has been considered for a broad array of diseases. Recent investigation has suggested that gene therapy may be applied to the treatment of diabetes mellitus and associated pathologies involving several organs. In the kidney, glomerulopathy is the most typical pathologic feature. This article addresses potential strategies towards gene therapy for diabetic glomerular disease.
FineL.G.Gene transfer into the kidney: Promise for unraveling disease mechanisms, limitations for gene therapy.Kidney Int.1996; 49: 612–19.
2.
KitamuraM., FineL.G.Gene transfer into the kidney: Promises and limitations.Kidney Int.1997; 52: S86–90.
3.
KitamuraM.Strategic gene transfer into the kidney: Current status and prospects.Clin Exper Nephrol.1997; 1: 157–78.
4.
MitanchezD., DoironB., ChenR.Glucose-stimulated genes and prospects of gene therapy for type I diabetes.Endocr Rev.1997; 18: 520–40.
5.
DochertyK.Gene therapy for diabetes mellitus.Clin Sci.1997; 92: 321–30.
6.
IsakaY., AkagiY., AndoY., ImaiE.Application of gene therapy to diabetic nephropathy.Kidney Int.1997; 52(Suppl 60): S100–3.
7.
TomitaN., HigakiJ., MorishitaR., KatoK., MikamiH., KanedaY.Direct in vivo gene introduction into rat kidney.Biochem Biophys Res Commun.1992; 186: 129–34.
8.
ImaiE., IsakaY., AkagiY., KanedaY.Gene transfer into the glomerulus by hemagglutinating virus of Japan (HV J)-liposome method. In: KitamuraM., ed. Genetic manipulation of the kidney.Exp Nephrol.1997; 5: 112–17.
9.
IsakaY., FujiwaraY., UedaN., KanedaY., KamadaT., ImaiE.Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet derived growth factor gene into the rat kidney.J Clin Invest.1993; 92: 2597–601.
10.
AkagiY., IsakaY., AraiM., KanekoT., TakenakaM., MoriyamaT.Inhibition of TGF -β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis.Kidney Int.1996; 50: 148–55.
11.
HeikkilaP., ParpalaT., LukkarinenO., WeberM., TryggvasonK.Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system -First step towards gene therapy of Alport syndrome.Gene Ther.1996; 3: 21–7.
12.
KitamuraM.Gene delivery into the glomerulus via mesangial cell vectors. In: KitamuraM., ed. Genetic manipulation of the kidney.Exp Nephrol.1997; 5: 118–25.
13.
KitamuraM., TaylorS., UnwinR., BurtonS., ShimizuF., FineL.G.Gene transfer into the rat renal glomerulus via a mesangial cell vector: Site-specific delivery, in situ amplification and sustained expression of an exogenous gene in vivo.J Clin Invest.1994; 94: 497–505.
14.
KitamuraM., BurtonS., YokooT., FineL.G.Gene delivery into the renal glomerulus by transfer of genetically engineered, autologous mesangial cells.Exp Nephrol.1996; 4: 56–9.
15.
KitamuraM., BurtonS., EnglishJ., KawachiH., FineL.G.Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-l response in the glomerulus.Kidney Int.1995; 48: 1747–57.
16.
YokooT., KitamuraM.Gene transfer of interleukin-l receptor antagonist into the renal glomerulus via a mesangial cell vector.Biochem Biophys Res Commun.1996; 226: 883–8.
17.
AbboudH.E.Growth factors and diabetic nephropathy: An overview.Kidney Int.1997; 52(Suppl 60): S3–6.
18.
ZiyadehF.N., HanD.C.Involvement of transforming growth factor-β and its receptors in the pathogenesis of diabetic nephropathy.Kidney Int.1997; 52(Suppl 60): S7–11.
19.
IhmC-GMonocyte chemotactic peptide-l in diabetic nephropathy.Kidney Int.1997; 52(Suppl 60): S20–1.
20.
TomosugiN., YamayaS., KimuraK., SakamotoK., WatanabeK., TakataM.Antisense oligonucleotides for MCP-l partially suppress glomerular macrophage infiltration in anti-GBM antibody nephritis [Abstract].J Am Soc Nephrol.1996; 7: 1748.
21.
KashiharaN., MaeshimaY., SekikawaT., OkamotoK., KanaoK., SugiyamaH.Inhibition of human mesangial cell proliferation by decoy oligonucleotide targeting the transcription factor, NF -KB [Abstract].J Am Soc Nephrol.1995; 6: 834.
22.
MorishitaR., TomitaN., GibbonsG.H., TomitaS., ZhangL., KanedaY.Potential gene therapy for glomerulonephritis: Transfection of NF-KB decoy inhibited TNF -α induced cytokines and adhesion molecules expression in vivo [Abstract].J Am Soc Nephrol.1996; 7: 1711.
23.
TomitaN., MorishitaR., HashizumeM., YasudaM., NotakeM., FujitaniB.Feasibility of decoy strategy by targeting the transcription factor NF -KB in anti-GBM nephritis [Abstract].J Am Soc Nephrol.1997; 8: 467A.
24.
TomitaN., KimJ., GibbonsG.H., BaranD., OgbornM., StahlR.A.K.In vivo gene therapy of anti-Thy -l nephritis using E2F decoy oligonucleotide [Abstract].J Am Soc Nephrol.1995; 6: 887.
HanedaM., ArakiS., TogawaM., SugimotoT., IsonoM., KikkawaR.Activation of mitogen-activated protein kinase cascade in diabetic glomeruli and mesangial cells cultured under high glucose conditions.Kidney Int.1997; 52(Suppl 60): S66–9.
27.
KingG.L., IshiiH., KoyaD.Diabetic vascular dysfunctions: A model of excessive activation of protein kinase C.Kidney Int.1997; 52(Suppl 60): S77–85.
28.
KitamuraM., IshikawaY.Functional inactivation of signaling molecules via transdominant negative mutants.Exp Nephrol.1997; 5: 435–8.
29.
HeiligC.W., BrosiusF.C., HenryD.N.Glucose transporters of the glomerulus and the implications for diabetic nephropathy.Kidney Int.1997; 52(Suppl 60): S91–9.
30.
KitamuraM.Creation of a reversible on/off system for site-specific in vivo control of exogenous gene activity in the renal glomerulus.Proc Natl Acad Sci U S A.1996; 93: 7387–91.
31.
KitamuraM., KawachiH.Creation of an in vivo cytosensor using engineered mesangial cells: Automatic sensing of glomerular inflammation controls transgene activity.J Clin Invest.1997; 100: 1394–9.
